Skip to main content
    PeptideAuthority
    Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
    Share:X PostLinkedIn
    Fat Loss & Metabolic•Updated 2026-02-01•5 min read

    What Is GLP-1? Benefits, Research & Safety

    A naturally occurring gut hormone that regulates glucose metabolism and appetite, serving as the basis for major obesity and diabetes medications.

    Share:X PostLinkedIn
    Also known as:
    Glucagon-Like Peptide-1
    GLP-1 (7-36) amide
    Incretin
    AStrong human evidenceUK: Sold as 'research only' (UK)WADA: Sport status unclear

    UK summary: Endogenous gut hormone — not a medicine per se, but the basis of UK-licensed GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide). Native GLP-1 is too short-acting to be useful as a drug; this page is educational background.

    Quick Facts

    Category
    Fat Loss & Metabolic
    Half-Life
    1-2 minutes for native GLP-1 (rapidly degraded by DPP-4)
    UK Status
    Native GLP-1 not used; GLP-1 agonists are approved medications.
    EU Status
    Multiple GLP-1 receptor agonists approved for diabetes and obesity.

    Overview

    Glucagon-like peptide-1 (GLP-1) is a 30-amino acid peptide hormone produced primarily by L-cells in the small intestine in response to food intake. It is a member of the incretin hormone family and plays crucial roles in glucose homeostasis, appetite regulation, and energy balance. GLP-1 is released after eating and produces multiple metabolic effects: it enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes feelings of fullness by acting on brain regions controlling appetite. These combined actions make it a key regulator of post-meal metabolism. The challenge with native GLP-1 is its extremely short half-life—approximately 1-2 minutes—due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4). This has led to the development of GLP-1 receptor agonists (such as semaglutide and liraglutide) with modified structures that resist degradation, as well as DPP-4 inhibitors that slow the breakdown of endogenous GLP-1. Understanding GLP-1 biology has revolutionised the treatment of type 2 diabetes and obesity, leading to some of the most effective medications for these conditions ever developed.
    Evidence standards summary

    GLP-1 — evidence and risk at a glance

    Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

    01Evidence snapshot

    AStrong human evidenceOverall grade against our evidence grading methodology.

    Endogenous gut hormone — not a medicine per se, but the basis of UK-licensed GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide). Native GLP-1 is too short-acting to be useful as a drug; this page is educational background.

    02Human evidence grade

    AStrong human evidenceStrength of evidence from published human trials.

    03Preclinical evidence grade

    AStrong human evidenceAnimal-model and in-vitro evidence quality.

    04Regulatory status

    • UK: Native GLP-1 not used; GLP-1 agonists are approved medications.
    • EU: Multiple GLP-1 receptor agonists approved for diabetes and obesity.
    • Notes: The biological understanding of GLP-1 has led to the development of highly successful medications including semaglutide, liraglutide, and others.

    05Approved medical uses

    None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)

    06Unapproved / promotional claims

    • Oral 'GLP-1 boosters' raise natural GLP-1 levels and produce weight loss.
    • Bitter-melon, berberine, or natural GLP-1 supplements substitute for semaglutide.
    • Native GLP-1 peptide is available for injection and works like Ozempic.

    07Common internet claims

    • Marketed in supplements as 'natural GLP-1' or 'GLP-1 activators'.
    • Sold by some online retailers as research-only injectable GLP-1.
    • Promoted in wellness blogs as a lifestyle alternative to prescription GLP-1 agonists.

    08Claim vs evidence

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “GLP-1 supplements raise your natural GLP-1 levels”ENoHighNative GLP-1 has a half-life of minutes; oral 'GLP-1 boosting' supplements have no evidence base. Use a licensed GLP-1 receptor agonist via a UK prescription if clinically indicated.
    “GLP-1 is the same as Ozempic”ENoHighOzempic is semaglutide — a chemically modified analogue with a half-life of about a week. Native GLP-1 is the underlying biology, not the medicine.

    09Safety uncertainty score

    Moderate

    Safety profile partly characterised; some signals from observational or preclinical data.

    10Known adverse signals

    • Native GLP-1 is endogenous, with minutes-long half-life; the underlying biology is well characterised.
    • Injectable 'native GLP-1' from grey-market sources has unverified identity and sterility.
    • Supplement-route 'GLP-1 boosters' have no consistent safety profile because their actual mechanisms vary.

    11Drug-interaction uncertainty

    Low

    Drug-interaction picture documented in the prescribing information.

    12Anti-doping status

    WADA: Sport status unclearWADA strict-liability framing applies.

    13UK legal position

    UK: Sold as 'research only' (UK)

    Native GLP-1 not used; GLP-1 agonists are approved medications.

    Read the full UK legal guide → Semaglutide and UK law

    14EU legal position

    Multiple GLP-1 receptor agonists approved for diabetes and obesity.

    15What this page cannot tell you

    • Whether any oral 'GLP-1 booster' supplement actually raises GLP-1 in your body.
    • Whether injectable native-GLP-1 products contain GLP-1 or a different compound.
    • How injectable native GLP-1 would differ pharmacokinetically from licensed analogues (it would be far too short-acting to be useful).

    16Last reviewed

    Last reviewed:

    Next review due:

    Spotted an error or something out of date? Send a correction.

    17Citation quality score

    AStrong human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

    18Research gaps

    • Lifestyle interventions (diet composition, meal timing) that meaningfully modulate endogenous GLP-1 response are studied but effects are small versus pharmacological GLP-1 agonism.

    19Safer alternatives / established care pathways

    • Licensed GLP-1 receptor agonist (semaglutide, tirzepatide, liraglutide) via UK prescriber where clinically indicated.
    • Lifestyle interventions (Mediterranean-style diet, protein-adequate meals, regular exercise) that support normal incretin response.
    • NHS Tier 2 / Tier 3 weight management programmes for structured behaviour change.

    20Doctor discussion prompts

    Questions to ask a qualified clinician

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • Am I a candidate for a licensed GLP-1 receptor agonist (semaglutide, tirzepatide, liraglutide)?
    • What lifestyle approaches enhance natural incretin response?

    Discovery & History

    The discovery of GLP-1 emerged from research into the products of the proglucagon gene in the 1980s. While glucagon had been known since the 1950s, scientists discovered that the same gene encoded multiple peptides depending on where it was expressed. In the pancreas, proglucagon processing produces glucagon. In the intestine, different processing produces GLP-1 and GLP-2. The identification of GLP-1 and its potent insulinotropic effects in the early 1980s by several research groups generated significant interest. The observation that GLP-1 enhanced insulin secretion only when glucose was elevated—thus carrying low risk of hypoglycaemia—made it particularly attractive as a potential diabetes treatment. However, the extremely short half-life of native GLP-1 presented a significant therapeutic challenge. This led to two main therapeutic strategies: development of DPP-4-resistant GLP-1 analogues (GLP-1 receptor agonists like exenatide, liraglutide, and semaglutide) and development of DPP-4 inhibitors (like sitagliptin) that slow endogenous GLP-1 breakdown. The remarkable success of GLP-1-based therapies, culminating in semaglutide's unprecedented weight loss results, has validated the central importance of this hormone in metabolic regulation.

    Mechanism of Action

    GLP-1 exerts its effects through the GLP-1 receptor, a G protein-coupled receptor expressed in multiple tissues: **Pancreatic Effects** GLP-1 stimulates insulin secretion from beta cells in a strictly glucose-dependent manner—insulin is only released when blood glucose is elevated. It also inhibits glucagon secretion from alpha cells, reducing hepatic glucose output. **Gastric Effects** GLP-1 slows gastric emptying, delaying the delivery of nutrients to the small intestine. This contributes to lower post-meal glucose peaks and prolonged satiety. **Central Nervous System Effects** GLP-1 receptors in the hypothalamus and brainstem mediate appetite suppression and promote satiety. These central effects are a major contributor to the weight loss seen with GLP-1 therapies. **Cardiovascular Effects** GLP-1 receptors are expressed in the heart and blood vessels. GLP-1 may have direct cardioprotective effects, though the precise mechanisms are still being elucidated. **Beta Cell Preservation** Animal and cell studies suggest GLP-1 may promote beta cell survival and proliferation, though the relevance of this to long-term human treatment remains under investigation.

    Researched Benefits

    Based on preclinical and clinical research findings:

    • 1
      Glucose-dependent insulin secretion (low hypoglycaemia risk)
    • 2
      Improved glycaemic control in type 2 diabetes
    • 3
      Appetite suppression and weight loss
    • 4
      Delayed gastric emptying contributing to satiety
    • 5
      Potential beta cell preservation
    • 6
      Cardiovascular benefits observed with GLP-1 agonists

    Claim vs Evidence

    How popular claims about GLP-1 stack up against the current research, graded using our public evidence grading methodology.

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “GLP-1 supplements raise your natural GLP-1 levels”ENoHighNative GLP-1 has a half-life of minutes; oral 'GLP-1 boosting' supplements have no evidence base. Use a licensed GLP-1 receptor agonist via a UK prescription if clinically indicated.
    “GLP-1 is the same as Ozempic”ENoHighOzempic is semaglutide — a chemically modified analogue with a half-life of about a week. Native GLP-1 is the underlying biology, not the medicine.

    Theoretical Dosing & Protocols

    ⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
    Theoretical DosageNative GLP-1 is not used therapeutically due to short half-life
    FrequencyN/A for native GLP-1
    DurationN/A
    NotesNative GLP-1 is not practical for therapeutic use. Instead, GLP-1 receptor agonists (semaglutide, liraglutide) or DPP-4 inhibitors are used to achieve GLP-1-like effects.

    Administration Routes

    Routes studied in research settings (educational only):

    • Native GLP-1 would require continuous infusion (not practical)
    • GLP-1 analogues: subcutaneous injection or oral (for semaglutide)
    Half-LifeStability
    1-2 minutes for native GLP-1 (rapidly degraded by DPP-4)Native GLP-1 is highly unstable; analogues have been engineered for stability

    Safety Profile & Known Risks

    Commonly Reported Side Effects

    • Not applicable for native GLP-1 (not used therapeutically)
    • See semaglutide and liraglutide entries for GLP-1 agonist side effects

    Rare Risks & Concerns

    • GLP-1 agonist class effects include pancreatitis risk, gallbladder disease

    Contraindications

    • See specific GLP-1 agonist entries for contraindications

    UK & EU Regulatory Context

    🇬🇧 United Kingdom

    Native GLP-1 not used; GLP-1 agonists are approved medications.

    🇪🇺 European Union

    Multiple GLP-1 receptor agonists approved for diabetes and obesity.

    The biological understanding of GLP-1 has led to the development of highly successful medications including semaglutide, liraglutide, and others.

    Clinical Studies Summary

    Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis.

    The rest of the authors have no conflicts to declare. The relationships disclosed by the authors did not influence the design, conduct, or interpretation of the data presented in this study.

    Rev Endocr Metab Disord. 2026View on PubMed

    GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials.

    GLP-1 receptor agonists significantly increase the likelihood of weight loss versus placebo, with tirzepatide and semaglutide demonstrating the greatest relative efficacy among agents evaluated. These findings support GLP-1-based therapy as an effective component of clinical obesity management.

    Medicine (Baltimore). 2026View on PubMed

    Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.

    Potent GLP-1 RAs, such as tirzepatide and semaglutide, demonstrate greater overall weight loss but are associated with a significant reduction in lean mass. None is related to this paper. CSM recused himself from handling this paper.

    Metabolism. 2025View on PubMed

    Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials.

    We found evidence that GLP-1 receptor agonists significantly reduce clinically important kidney events, kidney failure, and cardiovascular events.

    Lancet Diabetes Endocrinol. 2025View on PubMed

    Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials.

    GLP-1 RAs demonstrated significant weight, BMI, and waist circumference reduction benefits in this meta-analysis.

    Diabetes Care. 2025View on PubMed

    The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis.

    This review underscores the potential role of GLP-1 agonists in BED management. However, given the limited data, especially concerning EDs other than BED and the long-term effects of these medications, further comprehensive clinical trials are recommended to evaluate the impact of various GLP-1 agonists on different EDs across diverse demographic groups.

    Eat Weight Disord. 2025View on PubMed

    Registered Trials & Regulatory Status

    Registered trials
    90
    Currently recruiting
    8
    Furthest phase
    Phase 4
    Approved product
    No

    48 of 56 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.

    The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans

    PHASE2

    Status: Not Yet Recruiting · 80 participants · Mayo Clinic

    Conditions: Genetic Predisposition, Type2diabetes

    No results postedNCT06972407

    Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.

    PHASE2

    Status: Not Yet Recruiting · 164 participants · Biophytis

    Conditions: Muscle Wasting, Obesity & Overweight, Obesity

    No results postedNCT07411378

    Incretin Therapies in Obesity-related HFpEF

    PHASE4

    Status: Not Yet Recruiting · 50 participants · Columbia University

    Conditions: Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Obesity

    No results postedNCT07554638

    The Antiemetic Effects of Increased Splanchnic Perfusion, Induced by the Gut Hormone GIP, in Healthy Individuals

    NA

    Status: Enrolling By Invitation · 14 participants · University of Copenhagen

    Conditions: Emesis

    No results postedNCT07687589

    Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity

    PHASE2

    Status: Recruiting · 20 participants · St. Jude Children's Research Hospital

    Conditions: Acute Lymphoblastic Leukemia, Obesity

    No results postedNCT07228741

    Dietary Insights and Nutritional Education in Adults on GLP-1 Therapy

    NA

    Status: Recruiting · 50 participants · University of South Carolina

    Conditions: Obesity Type 2 Diabetes Mellitus, Obesity

    No results postedNCT07518407

    Changes in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss Patients

    N/A

    Status: Recruiting · 150 participants · San Raffaele Telematic University

    Conditions: Obesity & Overweight, Taste Alterations, Weight Loss

    No results postedNCT07229170

    People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

    N/A

    Status: Recruiting · 100 participants · Northwestern University

    Conditions: Multiple Sclerosis

    No results postedNCT07207148

    The Role of Islet GLP-1 in the Pathogenesis of Prediabetes

    PHASE2

    Status: Recruiting · 60 participants · Mayo Clinic

    Conditions: PreDiabetes

    No results postedNCT06967558

    Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions

    PHASE4

    Status: Active Not Recruiting · 30 participants · Mayo Clinic

    Conditions: Obesity

    No results postedNCT06801015

    The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms

    PHASE4

    Status: Not Yet Recruiting · 60 participants · Taipei Veterans General Hospital, Taiwan

    Conditions: Glucagon-Like Peptide-1 Receptor Agonists, Type 2 Diabetes, Coronary Arterial Disease (CAD)

    No results postedNCT07073053

    GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)

    PHASE3

    Status: Recruiting · 420 participants · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    Conditions: Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes

    No results postedNCT07083154

    Adverse event reports (FDA FAERS)

    Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.

    Source: ClinicalTrials.gov and openFDA. Updated automatically.

    Looking for GLP-1?

    Source research-grade GLP-1 from a trusted UK supplier — third-party tested with certificate of analysis.

    View at Supplier

    Frequently Asked Questions

    Questions to ask a qualified clinician about GLP-1

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • Am I a candidate for a licensed GLP-1 receptor agonist (semaglutide, tirzepatide, liraglutide)?
    • What lifestyle approaches enhance natural incretin response?

    UK regulatory & safety context

    Semaglutide and UK law

    UK legal reference

    Related Peptides

    Semaglutide

    A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.

    Learn more

    Liraglutide

    An earlier GLP-1 receptor agonist approved for diabetes and weight management, offering once-daily dosing with proven efficacy and safety.

    Learn more

    Tirzepatide

    A first-in-class dual GLP-1 and GIP receptor agonist achieving unprecedented weight loss of up to 22% in clinical trials, approved for type 2 diabetes and obesity treatment.

    Learn more

    Explore More Peptides

    Browse our comprehensive database of research-backed peptide profiles.